Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD...
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in...
Cadrenal Therapeutics to Present at Upcoming Investor Conferences PR Newswire PONTE VEDRA, Fla., Aug. 14, 2024...
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update PR Newswire PONTE VEDRA, Fla., Aug. 7...
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.